Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vilnius University

Criteria

Inclusion Criteria:

• cancer patients undergoing anthracyclines based chemotherapy;

• heart rate (HR) > 70 times per minute;

• Written informed consent.

Exclusion Criteria:

• Contraindications for ivabradine administration;

• HR<70 times per minute;

• Incapability to complete informed consent;

• Severe valve disease;

• Left ventricular ejection fraction (LVEF)≤ 30 %;

• Other severe conditions;

• Poor echogenicity.